Al Marzooqi assumed his current position in 2023. He oversees population genomics, multi-omics, biobanking, environmental sciences, advanced diagnostics, and clinical trials. In 2026, M42’s Integrated Health Solutions Platform struck deals with biotechs and pharma on clinical trials such as Halia Therapeutics, Arcera Life Sciences. It also launched Abu Dhabi Biobank and eye bank with Bascom Palmer Eye Institute, as well as partnerships with BioTwin and Human Life Cord Japan. Al Marzooqi was previously COO at G42 Healthcare and chief administrative officer at Cleveland Clinic Abu Dhabi.